EML4 and non-small cell lung carcinoma: Inhibition of ALK autophosphorylation and phosphorylation of STAT3 and ALK (without ERK1/2) is the primary target of alectinib effective in NSCLC expressing EML4-ALK (Sakamoto et al., 2011).